论文部分内容阅读
再灌注治疗(溶栓或介入手术)是心肌梗死最有效的治疗手段,但会引起致命的心肌缺血/再灌注损伤。心肌缺血后采取治疗性浅低温疗法(32~35℃)可有效减少心肌梗死面积,提高ST段抬高型急性心肌梗死患者的远期生存率。治疗性浅低温疗法虽经过大量研究已经在很多方面达成了共识,然而其中的很多细节及其涉及的多种分子生物学机制仍需要进一步研究和完善。本文对心肌缺血/再灌注损伤中治疗性浅低温疗法的研究进展作一简要综述。
Reperfusion therapy (thrombolysis or interventional surgery) is the most effective treatment of myocardial infarction, but can cause fatal myocardial ischemia / reperfusion injury. Myocardial ischemia and treatment of mild hypothermia (32 ~ 35 ℃) can effectively reduce the infarct size and improve the long-term survival rate of patients with ST-elevation acute myocardial infarction. Although a great deal of research has been done on therapeutic hypothermia therapy, it has reached consensus in many aspects. However, many of the details and various molecular biological mechanisms involved in this field still need further study and improvement. This review summarizes the progress of therapeutic hypothermia in myocardial ischemia / reperfusion injury.